How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/infanrixtm.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

InfanrixTM — Competitive Intelligence Brief

InfanrixTM (InfanrixTM) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Combination vaccine (inactivated toxoid and acellular pertussis). Area: Immunology / Infectious Disease Prevention.

phase 3 Combination vaccine (inactivated toxoid and acellular pertussis) Immunology / Infectious Disease Prevention Biologic Live · refreshed every 30 min

Target snapshot

InfanrixTM (InfanrixTM) — GlaxoSmithKline. Infanrix is a combination vaccine that stimulates the immune system to produce antibodies against diphtheria, tetanus, and pertussis (whooping cough) pathogens.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
InfanrixTM TARGET	InfanrixTM	GlaxoSmithKline	phase 3	Combination vaccine (inactivated toxoid and acellular pertussis)
Comparator: Infanrix™	Comparator: Infanrix™	Merck Sharp & Dohme LLC	marketed	Combination vaccine (inactivated toxoid and acellular pertussis)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Combination vaccine (inactivated toxoid and acellular pertussis) class)

GlaxoSmithKline · 1 drug in this class
Merck Sharp & Dohme LLC · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). InfanrixTM — Competitive Intelligence Brief. https://druglandscape.com/ci/infanrixtm. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab